Topical application of fingolimod perturbs cutaneous inflammation

Journal of Immunology

Volumn 196, Issue 9, 2016, Pages 3854-3864

  Sun, Wai Y ^a,b   Dimasi, David P ^a   Pitman, Melissa R ^a   Zhuang, Yizhong ^b   Heddle, Robert ^b,c,d   Pitson, Stuart M ^a,b   Grimbaldeston, Michele A ^a,b   Bonder, Claudine S ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FINGOLIMOD; HISTAMINE; IMMUNOGLOBULIN E; MP A 08; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; PHOSPHOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DRUG INDICATION; DRUG REPOSITIONING; EAR; EAR EDEMA; ENZYME ACTIVITY; EXTRAVASATION; FEMALE; INFLAMMATION; INTRAVITAL MICROSCOPY; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MALE; MEDIATOR RELEASE; MOUSE; MOUSE MODEL; MULTIPLE SCLEROSIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SKIN ANAPHYLAXIS; VENULE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEUTROPHIL; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CAPILLARY PERMEABILITY; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DERMATITIS; DISEASE MODELS, ANIMAL; FINGOLIMOD HYDROCHLORIDE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; NEUTROPHILS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SKIN;

EID: 84974822383     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501510     Document Type: Article

References (78)

1. Holgate, S. T., and R. Polosa. 2008. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 8: 218-230.
2. Akdis, M., and C. A. Akdis. 2014. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J. Allergy Clin. Immunol. 133: 621-631.
3. Allen, D. B. 2006. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv. Pediatr. 53: 101-110.
4. Patel, D. A., D. A. Holdford, E. Edwards, and N. V. Carroll. 2011. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J. Allergy Clin. Immunol. 128: 110-115.e5.
5. Australasian Society of Clinical Immunology and Allergy. 2014. Food allergy and anaphylaxis update: 2014. Available at: https://www.allergy.org.au/images/stories/hp/info/ASCIA-food-allergy-and-anaphylaxis-update-April-2014.pdf.
6. Burns, A. R., R. A. Bowden, Y. Abe, D. C. Walker, S. I. Simon, M. L. Entman, and C. W. Smith. 1999. P-selectin mediates neutrophil adhesion to endothelial cell borders. J. Leukoc. Biol. 65: 299-306.
7. Sur, S., T. B. Crotty, G. M. Kephart, B. A. Hyma, T. V. Colby, C. E. Reed, L. W. Hunt, and G. J. Gleich. 1993. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. 148: 713-719.
8. Fahy, J. V., K. W. Kim, J. Liu, and H. A. Boushey. 1995. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 95: 843-852.
9. Oyoshi, M. K., R. He, Y. Li, S. Mondal, J. Yoon, R. Afshar, M. Chen, D. M. Lee, H. R. Luo, A. D. Luster, et al. 2012. Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. Immunity 37: 747-758.
10. Carroll, N. G., S. Mutavdzic, and A. L. James. 2002. Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 57: 677-682.
11. Alcañ iz, L., A. Vega, P. Chacón, R. El Bekay, I. Ventura, R. Aroca, M. Blanca, D. T. Bergstralh, and J. Monteseirin. 2013. Histamine production by human neutrophils. FASEB J. 27: 2902-2910.
12. Pillay, J., I. den Braber, N. Vrisekoop, L. M. Kwast, R. J. de Boer, J. A. Borghans, K. Tesselaar, and L. Koenderman. 2010. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 116: 625-627.
13. Shi, J., G. E. Gilbert, Y. Kokubo, and T. Ohashi. 2001. Role of the liver in regulating numbers of circulating neutrophils. Blood 98: 1226-1230.
14. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: N1 versus N2 TAN. Cancer Cell 16: 183-194.
15. Olivera, A., T. Kohama, L. Edsall, V. Nava, O. Cuvillier, S. Poulton, and S. Spiegel. 1999. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147: 545-558.
16. Pitson, S. M., R. J. D'andrea, L. Vandeleur, P. A. Moretti, P. Xia, J. R. Gamble, M. A. Vadas, and B. W. Wattenberg. 2000. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem. J. 350: 429-441.
17. Pitson, S. M., P. A. Moretti, J. R. Zebol, H. E. Lynn, P. Xia, M. A. Vadas, and B. W. Wattenberg. 2003. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22: 5491-5500.
18. Kharel, Y., M. Raje, M. Gao, A. M. Gellett, J. L. Tomsig, K. R. Lynch, and W. L. Santos. 2012. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem. J. 447: 149-157.
19. Cordts, F., S. Pitson, C. Tabeling, I. Gibbins, D. F. Moffat, H. Jersmann, S. Hodge, and R. V. Haberberger. 2011. Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease. Life Sci. 89: 806-811.
20. Allende, M. L., T. Sasaki, H. Kawai, A. Olivera, Y. Mi, G. van Echten-Deckert, R. Hajdu, M. Rosenbach, C. A. Keohane, S. Mandala, et al. 2004. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279: 52487-52492.
21. Mizugishi, K., T. Yamashita, A. Olivera, G. F. Miller, S. Spiegel, and R. L. Proia. 2005. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25: 11113-11121.
22. Shimamura, K., Y. Takashiro, N. Akiyama, T. Hirabayashi, and T. Murayama. 2004. Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells. Eur. J. Pharmacol. 486: 141-150.
23. Sensken, S. C., C. Bode, M. Nagarajan, U. Peest, O. Pabst, and M. H. Gräler. 2010. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J. Immunol. 184: 4133-4142.
24. Weis, T., W. Völker, R. Holtwick, M. Al Chahaf, and A. Schmidt. 2010. Sphingosine 1-phosphate (S1P) induces expression of E-selectin and adhesion of monocytes via intracellular signalling pathways in vascular endothelial cells. Eur. J. Cell Biol. 89: 733-741.
25. Roviezzo, F., V. Brancaleone, L. De Gruttola, V. Vellecco, M. Bucci, B. D'Agostino, D. Cooper, R. Sorrentino, M. Perretti, and G. Cirino. 2011. Sphingosine-1-phosphate modulates vascular permeability and cell recruitment in acute inflammation in vivo. J. Pharmacol. Exp. Ther. 337: 830-837.
26. Hsieh, H. L., C. C. Sun, C. B. Wu, C. Y. Wu, W. H. Tung, H. H. Wang, and C. M. Yang. 2008. Sphingosine 1-phosphate induces EGFR expression via Akt/NF-kB and ERK/AP-1 pathways in rat vascular smooth muscle cells. J. Cell. Biochem. 103: 1732-1746.
27. Bonder, C. S., W. Y. Sun, T. Matthews, C. Cassano, X. Li, H. S. Ramshaw, S. M. Pitson, A. F. Lopez, P. T. Coates, R. L. Proia, et al. 2009. Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation. Blood 113: 2108-2117.
28. Lin, C. I., C. N. Chen, P. W. Lin, and H. Lee. 2007. Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3. Biochem. Biophys. Res. Commun. 355: 895-901.
29. Sun,W. Y., L. D. Abeynaike, S. Escarbe, C. D. Smith, S. M. Pitson, M. J. Hickey, and C. S. Bonder. 2012. Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. Am. J. Pathol. 180: 1740-1750.
30. Rivera, J., R. L. Proia, and A. Olivera. 2008. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8: 753-763.
31. Oskeritzian, C. A., N. C. Hait, P. Wedman, A. Chumanevich, E. M. Kolawole, M. M. Price, Y. T. Falanga, K. B. Harikumar, J. J. Ryan, S. Milstien, et al. 2015. The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. J. Allergy Clin. Immunol. 135: 1008-18.e1.
32. Ammit, A. J., A. T. Hastie, L. C. Edsall, R. K. Hoffman, Y. Amrani, V. P. Krymskaya, S. A. Kane, S. P. Peters, R. B. Penn, S. Spiegel, and R. A. Panettieri, Jr. 2001. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J. 15: 1212-1214.
33. Michaud, J., M. Kohno, R. L. Proia, and T. Hla. 2006. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett. 580: 4607-4612.
34. Kharel, Y., S. Lee, A. H. Snyder, S. L. Sheasley-O'neill, M. A. Morris, Y. Setiady, R. Zhu, M. A. Zigler, T. L. Burcin, K. Ley, et al. 2005. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280: 36865-36872.
35. Brinkmann, V., A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, and P. Burtin. 2010. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9: 883-897.
36. Paugh, S. W., S. G. Payne, S. E. Barbour, S. Milstien, and S. Spiegel. 2003. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554: 189-193.
37. Tonelli, F., K. G. Lim, C. Loveridge, J. Long, S. M. Pitson, G. Tigyi, R. Bittman, S. Pyne, and N. J. Pyne. 2010. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell. Signal. 22: 1536-1542.
38. Price, M. M., C. A. Oskeritzian, Y. T. Falanga, K. B. Harikumar, J. C. Allegood, S. E. Alvarez, D. Conrad, J. J. Ryan, S. Milstien, and S. Spiegel. 2013. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J. Allergy Clin. Immunol. 131: 501-11.e1.
39. Gendron, D., A. M. Lemay, C. Tremblay, L. J. Lai, A. Langlois, É . Bernatchez, N. Flamand, M. R. Blanchet, A. S. Don, Y. Bossé, et al. 2015. Treatment with a sphingosine analog after the inception of house dust mite-induced airway inflammation alleviates key features of experimental asthma. Respir. Res. 16: 7.
40. French, K. J., R. S. Schrecengost, B. D. Lee, Y. Zhuang, S. N. Smith, J. L. Eberly, J. K. Yun, and C. D. Smith. 2003. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63: 5962-5969.
41. Pitman, M. R., J. A. Powell, C. Coolen, P. A. Moretti, J. R. Zebol, D. H. Pham, J. W. Finnie, A. S. Don, L. M. Ebert, C. S. Bonder, et al. 2015. A selective ATPcompetitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget 6: 7065-7083.
42. Yip, K. H., N. Kolesnikoff, C. Yu, N. Hauschild, H. Taing, L. Biggs, D. Goltzman, P. A. Gregory, P. H. Anderson, M. S. Samuel, et al. 2014. Mechanisms of vitamin D3 metabolite repression of IgE-dependent mast cell activation. J. Allergy Clin. Immunol. 133: 1356-1364, 1364.e1-1364.e14.
43. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
44. Egawa, G., S. Nakamizo, Y. Natsuaki, H. Doi, Y. Miyachi, and K. Kabashima. 2013. Intravital analysis of vascular permeability in mice using two-photon microscopy. Sci. Rep. 3: 1932.
45. Rasband, W. S. 1997-2012. ImageJ. U.S. National Institutes of Health, Bethesda, MD. Available at: http://rsb.info.nih.gov/ij/.
46. Heddle, R., and B. Tao. 2002. Guidelines for performing a skin prick test. Med. Today 3: 67-70.
47. Ontaneda, D., and J. A. Cohen. 2011. Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev. Clin. Pharmacol. 4: 567-570.
48. Koh, K. J., A. L. Pearce, G. Marshman, J. J. Finlay-Jones, and P. H. Hart. 2002. Tea tree oil reduces histamine-induced skin inflammation. Br. J. Dermatol. 147: 1212-1217.
49. Budde, K., R. L. Schmouder, R. Brunkhorst, B. Nashan, P. W. Lucker, T. Mayer, S. Choudhury, A. Skerjanec, G. Kraus, and H. H. Neumayer. 2002. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13: 1073-1083.
50. Olivera, A., K. Mizugishi, A. Tikhonova, L. Ciaccia, S. Odom, R. L. Proia, and J. Rivera. 2007. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 26: 287-297.
51. Sun, W. Y., S. M. Pitson, and C. S. Bonder. 2010. Tumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial a5b1 integrin. Am. J. Pathol. 177: 436-446.
52. Pitman, M. R., J. M. Woodcock, A. F. Lopez, and S. M. Pitson. 2012. Molecular targets of FTY720 (fingolimod). Curr. Mol. Med. 12: 1207-1219.
53. Vessey, D. A., M. Kelley, J. Zhang, L. Li, R. Tao, and J. S. Karliner. 2007. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J. Biochem. Mol. Toxicol. 21: 273-279.
54. Lahiri, S., H. Park, E. L. Laviad, X. Lu, R. Bittman, and A. H. Futerman. 2009. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J. Biol. Chem. 284: 16090-16098.
55. Woodcock, J. M., Y. Ma, C. Coolen, D. Pham, C. Jones, A. F. Lopez, and S. M. Pitson. 2010. Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell. Signal. 22: 1291-1299.
56. Dawson, G., and J. Qin. 2011. Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochem. Biophys. Res. Commun. 404: 321-323.
57. Payne, S. G., C. A. Oskeritzian, R. Griffiths, P. Subramanian, S. E. Barbour, C. E. Chalfant, S. Milstien, and S. Spiegel. 2007. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109: 1077-1085.
58. Bozic, C. R., L. F. Kolakowski, Jr., N. P. Gerard, C. Garcia-Rodriguez, C. von Uexkull-Guldenband, M. J. Conklyn, R. Breslow, H. J. Showell, and C. Gerard. 1995. Expressi on and biologic characterization of the murine chemokine KC. J. Immunol. 154: 6048-6057.
59. Matsubara, M., K. Ohmori, and K. Hasegawa. 2006. Histamine H1 receptorstimulated interleukin 8 and granulocyte macrophage colony-stimulating factor production by bronchial epithelial cells requires extracellular signal-regulated kinase signaling via protein kinase C. Int. Arch. Allergy Immunol. 139: 279-293.
60. Wershil, B. K., Z. S. Wang, J. R. Gordon, and S. J. Galli. 1991. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J. Clin. Invest. 87: 446-453.
61. Baatz, H., M. Steinbauer, A. G. Harris, and F. Krombach. 1995. Kinetics of white blood cell staining by intravascular administration of rhodamine 6G. Int. J. Microcirc. Clin. Exp. 15: 85-91.
62. Brinkmann, V., M. D. Davis, C. E. Heise, R. Albert, S. Cottens, R. Hof, C. Bruns, E. Prieschl, T. Baumruker, P. Hiestand, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277: 21453-21457.
63. Chiba, K., Y. Yanagawa, Y. Masubuchi, H. Kataoka, T. Kawaguchi, M. Ohtsuki, and Y. Hoshino. 1998. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160: 5037-5044.
64. Pinschewer, D. D., A. F. Ochsenbein, B. Odermatt, V. Brinkmann, H. Hengartner, and R. M. Zinkernagel. 2000. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164: 5761-5770.
65. Mandala, S., R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, J. Milligan, R. Thornton, G. J. Shei, D. Card, C. Keohane, et al. 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
66. Kleinjan, A., M. van Nimwegen, K. Leman, H. C. Hoogsteden, and B. N. Lambrecht. 2013. Topical treatment targeting sphingosine-1-phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model. Allergy 68: 204-212.
67. Reines, I., M. Kietzmann, R. Mischke, T. Tschernig, A. Luth, B. Kleuser, and W. Bäumer. 2009. Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J. Invest. Dermatol. 129: 1954-1962.
68. Muller, H. C., A. C. Hocke, K. Hellwig, B. Gutbier, H. Peters, S. M. Schönrock, T. Tschernig, A. Schmiedl, S. Hippenstiel, P. D. N'Guessan, et al. 2011. The Sphingosine-1 phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulm. Pharmacol. Ther. 24: 377-385.
69. Nussbaum, C., S. Bannenberg, P. Keul, M. H. Gräler, C. F. Gonçalves-de-Albuquerque, H. Korhonen, K. von Wnuck Lipinski, G. Heusch, H. C. de Castro Faria Neto, I. Rohwedder, et al. 2015. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. Nat. Commun. 6: 6416.
70. Chen, B., S. G. Roy, R. J. McMonigle, A. Keebaugh, A. N. McCracken, E. Selwan, R. Fransson, D. Fallegger, A. Huwiler, M. T. Kleinman, et al. 2016. Azacyclic FTY720 analogues that limit nutrient transporter expression but lack S1P receptor activity and negative chronotropic effects offer a novel and effective strategy to kill cancer cells in vivo. ACS Chem. Biol. 11: 409-414.
71. Fitzpatrick, T. B. 1988. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 124: 869-871.
72. Galli, S. J., M. Tsai, and A. M. Piliponsky. 2008. The development of allergic inflammation. Nature 454: 445-454.
73. Jung, S. H., X. Sun, W. S. Ryu, and B. S. Yang. 2013. Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice. Br. J. Dermatol. 168: 112-119.
74. Azuma, M., P. Ritprajak, and M. Hashiguchi. 2010. Topical application of siRNA targeting cutaneous dendritic cells in allergic skin disease. Methods Mol. Biol. 623: 373-381.
75. Azam, P., A. Sankaranarayanan, D. Homerick, S. Griffey, and H. Wulff. 2007. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 127: 1419-1429.
76. Lin, T. K., M. Q. Man, J. L. Santiago, K. Park, T. Roelandt, Y. Oda, M. Hupe, D. Crumrine, H. J. Lee, M. Gschwandtner, et al. 2013. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J. Invest. Dermatol. 133: 469-478.
77. Kahan, B. D., J. L. Karlix, R. M. Ferguson, A. B. Leichtman, S. Mulgaonkar, T. A. Gonwa, A. Skerjanec, R. L. Schmouder, and L. Chodoff. 2003. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76: 1079-1084.
78. Pawankar, R., C. E. Baena-Cagnani, J. Bousquet, G. W. Canonica, A. A. Cruz, M. A. Kaliner, and B. Q. Lanier. 2008. State of world allergy report 2008: allergy and chronic respiratory diseases. World Allergy Organ. J. 1(6, Suppl.): S4-S17.